QuantHealth, a company specializing in AI-based clinical trial simulations, has announced a strategic investment from Sanofi Ventures, the venture capital division of global healthcare company Sanofi. This funding brings QuantHealth’s total capital raised to approximately $30 million and is expected to accelerate the development and application of patient-level simulations and digital twin technologies within pharmaceutical research and development.
We’re proud to welcome Sanofi Ventures as an investor and strategic ally in our journey. Sanofi is at the forefront of digital transformation in pharma, and this relationship will help us scale our impact and bring more predictive, AI-driven approaches to clinical development.
Orr Inbar, CEO and Co-founder of QuantHealth
QuantHealth’s proprietary platform leverages real-world datasets and machine learning models to generate large-scale patient-level digital twins. These computational models are designed to forecast the outcomes of clinical trials and to optimize trial design parameters. The approach is intended to address persistent challenges in drug development, including high trial failure rates, prolonged timelines, and escalating costs.
QuantHealth has the potential to transform how clinical trials are designed and optimized. Their approach to leveraging digital twins and real-world data is advancing the next generation of R&D, and I look forward to supporting the team.
Cris De Luca, Partner at Sanofi Ventures
According to the company, its simulation framework enables the generation of millions of individualized digital twin profiles, which can be used to assess the likelihood of trial success under different design conditions. By providing predictive insights prior to trial initiation, the platform seeks to enhance decision-making and resource allocation for pharmaceutical developers.
At Sanofi, we are building an AI-first organization, and engaging with innovators like QuantHealth is central to our strategy. Their platform represents an important opportunity to reimagine clinical trial design through simulation, and we’re excited to explore this capability together.
Emmanuel Frenehard, Chief Digital Officer at Sanofi
The partnership also formalizes a broader strategic alignment with Sanofi’s ongoing efforts to embed advanced AI and digital technologies across its R&D infrastructure. As part of the investment, Cris De Luca, Partner at Sanofi Ventures, will serve as a Board Observer for QuantHealth, contributing to the company’s governance and strategic direction.